Novel antibacterial silver nanomaterials have become promising substitutes for traditional antibiotics, because pathogens do not develop resistance to them. However, it is necessary to produce silver nanoparticles with appropriate size and better performance through a green and simple synthesis process. In the present study, Fructus mori-composite silver nanoparticles (M-AgNPs) were greenly synthesized using medicinal plant mulberry fruits (Fructus mori), with silver nitrate (AgNO3) as a precursor. UV-Vis spectroscopy and X-ray diffraction (XRD) indicated the formation of silver nanoparticles with face centered cubic structure. Fourier transform infrared (FTIR) spectroscopy confirmed the reducing and capping effects of mulberry fruits' active components (polyphenols, flavonoids, etc.) on M-AgNPs. The reaction parameters including temperature, time, pH, and concentration of AgNO3 were gradually optimized. The particle size and morphology of M-AgNPs were measured by dynamic light scattering (DLS) and transmission electron microscopy (TEM) techniques. The minimum particle size of M-AgNPs was about 30 nm, and they were approximately spherical and equably distributed. The excellent stability of M-AgNPs ensured that no agglomeration occurred for up to 60 days. The antioxidant activity of M-AgNPs was evaluated by 1,1-diphenyl-2-trinitrophenylhydrazine (DPPH) assay, and the DPPH radical clearance rate of M-AgNPs was up to about 79%. Greenly synthesized M-AgNPs exhibited better antibacterial activity than chemically synthesized commercial silver nanoparticles (C-AgNPs), due to the active molecules attached to their surfaces. The inhibition zone diameters of M-AgNPs against P.aeruginosa, E.coli and S.aureus were 13.9±0.4、12.2±0.3、12.8±0.7 mm, respectively. Such greenly synthesized AgNPs from medicinal plants have good prospects in the field of biomedicine.

For centuries, Foeniculi fructus (F. fructus) has been used as a traditional herbal medicine in China and Europe and is widely used as a natural therapy for digestive disorders, including indigestion, flatulence, and bloating. The mechanism by which F. fructus alleviates functional dyspepsia was analyzed through network pharmacology, and its therapeutic effect on an animal model of functional dyspepsia was investigated. The compounds, targets, and related diseases of F. fructus were studied utilizing the traditional Chinese medicine systems pharmacology (TCMSP) database. Information on the target genes was classified using the UniProt database. A network was built using Cytoscape 3.9.1, and functional dyspepsia-related genes were checked using the Cytoscape string application. The efficacy of F. fructus on functional dyspepsia, including gastroparesis and gastrointestinal motility, was confirmed by treatment with its extract in a mouse model of loperamide-induced functional dyspepsia. Seven compounds targeted twelve functional dyspepsia-associated genes. In a functional dyspepsia mouse model, F. fructus significantly suppressed the symptoms when compared to that in the control group. Our animal studies showed that the mechanism of action of F. fructus is closely related to gastrointestinal motility. Based on animal experimental results, the results showed that F. fructus provides a potential means to treat functional dyspepsia, suggesting that its medical mechanism for functional dyspepsia can be described by the relationship between seven key compounds of F. fructus, including oleic acid and β-sitosterol, and 12 functional dyspepsia-related genes.

Background: Hepatocellular carcinoma (HCC) is one of the most prevalent cancers in human populations worldwide. Conversely, Huanglian Decoction is one of the most important Chinese medicine formulas, with the potential to treat cancer. Methods: To identify differentially expressed genes (DEG), we herein downloaded gene expression profile data from the TCGA (TCGA-LIHC) and GEO (GSE45436) databases. We obtained phytochemicals of the four constituent herbs of Huanglian Decoction from the traditional Chinese medicine systems pharmacology database and analysis platform (TCMSP). We also established a regulatory network of DEG and their drug target genes and subsequently analyzed key genes using bioinformatic approaches. Furthermore, we explored the effect of Huanglian Decoction by conducting in vitro experiments so as to verify the prediction. In particular, the CCNB1 gene was knockdown to verify the primary target of this Decoction. Results: Based on the results of network pharmacological analysis, we revealed that there are 5 bioactive compounds in Huanglian Decoction acting on HCC. In addition, our findings confirmed that CCNB1 was the primary key gene, which can be highly expressed in tumors and was significantly associated with a worse prognosis (P = 0.002) according to PPI network analysis of the target genes of these five compounds, as well as expression and prognosis analyses in tumors. We also noted that CCNB1 can be used as an independent prognostic indicator of HCC (P < 0.01). Moreover, in vitro experimental results demonstrate that Huanglian Decoction can significantly inhibit the growth, migration, and invasion of HCC cells. Finally, further analysis showed that this Decoction may inhibit the growth of HCC cells by down-regulating the expression level of CCNB1.